Aligos Therapeutics (ALGS) Equity Average (2021 - 2025)
Historic Equity Average for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to $86.8 million.
- Aligos Therapeutics' Equity Average rose 4804.94% to $86.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.8 million, marking a year-over-year increase of 4804.94%. This contributed to the annual value of $31.6 million for FY2024, which is 6779.93% down from last year.
- As of Q3 2025, Aligos Therapeutics' Equity Average stood at $86.8 million, which was up 4804.94% from $109.2 million recorded in Q2 2025.
- Aligos Therapeutics' Equity Average's 5-year high stood at $200.9 million during Q4 2021, with a 5-year trough of $10.6 million in Q4 2024.
- Over the past 5 years, Aligos Therapeutics' median Equity Average value was $90.6 million (recorded in 2023), while the average stood at $104.9 million.
- In the last 5 years, Aligos Therapeutics' Equity Average plummeted by 8562.09% in 2024 and then soared by 7186.46% in 2025.
- Over the past 5 years, Aligos Therapeutics' Equity Average (Quarter) stood at $200.9 million in 2021, then tumbled by 43.77% to $113.0 million in 2022, then tumbled by 34.97% to $73.5 million in 2023, then tumbled by 85.62% to $10.6 million in 2024, then surged by 722.32% to $86.8 million in 2025.
- Its Equity Average was $86.8 million in Q3 2025, compared to $109.2 million in Q2 2025 and $43.7 million in Q1 2025.